546 The FSTL1-DIP2A axis as a promising target in the anti-PD1 therapy of advanced gastric cancer

• Naoki Takahashi,
• Hirokazu Shoji,
• Kengo Nagashima,
• Hiroshi Imazeki,
• Narikazu Boku,
• Takeshi Kawakami,
• Kei Muro,
• Takeru Wakatsuki,
• Chie Kudo-Saito,
• Yukiya Narita,
• Kai Tsugaru,
• Yusuke Amanuma,
• Naohiro Okano,
• Yoshiyuki Yamamoto,
• Rika Kizawa,
• Kazunori Aoki

Affiliations

Naoki Takahashi

3Saitama Cancer Center, Saitama, Japan

Hirokazu Shoji

1 G-SPIRIT Study Group, Chiba, Japan

Kengo Nagashima

Research Center for Medical and Health Data Science, The Institute of Statistical Mathematics, Tachikawa, Tokyo, Japan

Hiroshi Imazeki

Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

Narikazu Boku

Department of Oncology and General Medicine, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Takeshi Kawakami

Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan

Kei Muro

8Aichi Cancer Center Hospital, Nagoya, Japan

Takeru Wakatsuki

Department of Gastroenterology, Cancer Institute Hospital Gastroenterology Center, Koto-ku, Tokyo, Japan

Chie Kudo-Saito

Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan

Yukiya Narita

Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

Kai Tsugaru

2Keio University Hospital, Tokyo, Japan

Yusuke Amanuma

5Chiba Cancer Center, Chiba, Japan

Naohiro Okano

7Kyorin University Faculty of Medicine, Tokyo, Japan

Yoshiyuki Yamamoto

9University of Tsukuba Hospital, Ibaraki, Japan

Rika Kizawa

10Toranomon Hospital, Tokyo, Japan

Kazunori Aoki

1National Cancer Center, Tokyo, Japan